Tonix Pharmaceuticals Holding Corp (TNXP) FinancialsTNXPFinancialTonix Pharmaceuticals Holding Corp

Evaluating the bottom line, Tonix Pharmaceuticals Holding Corp. maintains a gross margin of 94.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -314.05%, while the net margin is -299.41%. These profitability ratios, combined with a Return on Equity (ROE) of -81.82%, provide a clear picture of how effectively TNXP converts its operational activities into shareholder value.

In the context of the broader market, TNXP competes directly with industry leaders such as NERV and TARA. With a market capitalization of $232.57M, it holds a significant position in the sector. When comparing efficiency, TNXP's gross margin of 94.81% stands against NERV's N/A and TARA's N/A. Such benchmarking helps identify whether Tonix Pharmaceuticals Holding Corp. is trading at a premium or discount relative to its financial performance.

Tonix Pharmaceuticals has shown a strong revenue increase, reporting $13.54 million in Q2 2026, significantly up from $2 million year-over-year. The gross margin has improved to 94.81%, indicating effective cost management and product acceptance in the market.